Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
No Data
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
TipRanks01:10 ET
CRISPR Therapeutics(CRSP.US) Officer Sells US$1.17 Million in Common Stock
$CRISPR Therapeutics(CRSP.US)$ Officer Kulkarni Samarth sold 19,582 shares of common stock on Apr 15, 2024 at an average price of $59.9138 for a total value of $1.17 million.Source: Announcement What
moomoo News18:28 ET
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing
Samarth Kulkarni, Director, Chief Executive Officer, on April 15, 2024, sold 19,582 shares in Crispr Therapeutics (CRSP) for $1,173,232. Following the Form 4 filing with the SEC, Kulkarni has control
MT Newswires17:51 ET
Bullish Trendline Has Never Failed Crispr Therapeutics Stock
Schaeffer's Investment Research12:58 ET
Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush
Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush
Dow Jones12:37 ET
Vertex Pharmaceuticals Hits 18-week Low
Trading Economics12:32 ET